<DOC>
	<DOCNO>NCT02522208</DOCNO>
	<brief_summary>This study investigate cardiovascular parameter use echocardiographic pharmacokinetics daily dose BiDil BiDil Extended Release ( XR ) compare study drug free day .</brief_summary>
	<brief_title>Pharmacodynamic Pharmacokinetic Study BiDil Extended-release Capsules Commercial BiDil Tablets</brief_title>
	<detailed_description>A multiple-center , open-label , randomize , daily dose , two-sequence , two-way crossover pharmacodynamics ( PD ) pharmacokinetic ( PK ) study BiDil XR capsule commercial BiDil tablets Self-identified Black Patients , Slow Acetylators , Heart Failure receive BiDil , isosorbide dinitrate ( ISDN ) , hydralazine hydrochloride ( HCl ) least 30 day prior screen . The study consist two dos BiDil XR capsule ( dosed 0 hr 9 hr ) three dos BiDil tablet ( dosed 0 hr , 6 hr 12 hr ) .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Isosorbide-5-mononitrate</mesh_term>
	<mesh_term>Isosorbide Dinitrate</mesh_term>
	<mesh_term>Hydralazine</mesh_term>
	<mesh_term>Isosorbide</mesh_term>
	<criteria>Selfidentified Black , stable , chronic heart failure male female subject classify New York Heart Association ( NYHA ) Class II III , diagnose least 3 month prior Screening . Clinically stable outpatient , receive standard , stable treatment regimen heart failure ( HF ) , least 2 week prior screen throughout duration trial . Subjects receive betablockers must take least 3 month . All medication must stable dose least 2 week prior first dose Subjects must receive BiDil , isosorbide dinitrate hydralazine HCl least 30 day prior Screening Have adequate demonstrable baseline Tricuspid regurgitation jet , visible inferior vena cava , adequate right heart echocardiogram ( without saline bubble contrast ) allow measurement make . Baseline PA systolic pressure &gt; 35 mmHg Slow acetylator Adult subject least 18 year old statespecific age majority . Clinical lab test negative HIV , Hepatitis B surface antigen Hepatitis C antibody . Urine test negative alcohol drug abuse . Negative human chorionic gonadotropin ( hCG ) pregnancy test . Females must agree avoid become pregnant male must agree use appropriate contraceptive method partner ( ) , study post 30 day last dose study drug . Females must : unable child partner sterile OR willing remain abstinent OR willing use two effective method birth control . Willing able confine inpatient study period agree study restriction Ability grant voluntary inform consent participate study . Have significant valvular heart disease , hemodynamically significant obstructive hypertrophic cardiomyopathy , active myocarditis , uncontrolled hypertension . Presence severe , clinical right heart failure . Symptoms unstable angina , myocardial infarction , cardiac surgery , percutaneous coronary intervention within 1 month prior Screening Have coronary artery disease likely require coronary artery bypass graft percutaneous coronary intervention ensue 3 month . Had cardiac arrest sustain ventricular tachycardia consider life threaten require intervention within 3 month , unless treat implantable cardioverterdefibrillator . cause pulmonary hypertension may confound pharmacodynamic assessment heart failure Active malignancy noncardiac lifelimiting disease . Have significant hepatic , renal , disease might confound study result present risk subject . Had stroke within past 3 month . Received parenteral inotropic therapy within 1 month . Likelihood undergoing cardiac transplantation circulatory assist device implant ensue 3 month . Symptomatic hypotension blood pressure le 110/70 mmHg Screening . Any condition risk factor would jeopardize evaluation efficacy safety ability obtain effective echocardiography result . Currently require riociguat , hydralazine HCl , longacting nitrate like ISDN , isosorbide mononitrate sustain release nitroglycerin phosphodiesterase 5 inhibitor . Alcohol drug abuse within 1 year study participation . Hypersensitivity , allergy , idiosyncratic reaction adverse reaction caffeine ( slow acetylator test require ) , ISDN , hydralazine HCl , compound similar chemical characteristic . Received investigational drug within 30 day . Donated one pint blood , plasma , platelet within 30 day . Any subject , opinion Investigator , follow instruction . Pregnant , lactate plan get pregnant study History lupus erythematous lupus like syndrome . Use herbal preparation , grapefruit , grapefruit juice , Seville oranges/juice use phosphodiesterase inhibitor within 2 week first dose study drug throughout study . Employee Sponsor , investigative site contract research organization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>